Akeso's Groundbreaking Alzheimer's Treatment Approved for Clinical Trials in China Akeso, Inc. has received approval for clinical trials of AK152, a novel bispecific antibody targeting Aβ in Alzheimer's patients, marking a significant development in therapy.

Akeso's Groundbreaking Alzheimer's Treatment Approved for Clinical Trials in China #China #Hong_Kong #Alzheimer's #Akeso #AK152